Welcome
Support Centre
12 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Corneal Collagen Cross-linking with Riboflavin (C3R) with orthokeratology
Source of recordUK Trials
ISRCTNISRCTN29378493
Date ISRCTN assigned27/03/2008
Local reference number(s)CHAR1004
Public titleCorneal Collagen Cross-linking with Riboflavin (C3R) with orthokeratology
Scientific titlePilot study of corneal collagen cross-linking with riboflavin (C3R) with pre-operative orthokeratology
AcronymC3R
Disease/condition/study domainCorneal ectasia
Study hypothesisTo assess whether orthokeratology using a specifically designed contact lens could enhance the corneal flattening effect of collagen cross-linking by ultraviolet (UV) light with riboflavin (C3R) and reduce any pre-existing astigmatism and/or myopia.
Design/methodologyPilot randomised controlled trial
Research ethics reviewEthics approval received from Moorfields and Whittington Hospitals Research Ethics Committee on the 1st December 2006 (ref: 06/Q0504/106).
Countries of trialUnited Kingdom
Participants - inclusion criteriaCorneal ectasia (keratoconus, pellucid marginal degeneration or post-excimer laser corneal ectasia) in patients intolerant or with limited tolerance of contact lenses. The only other options would be INTACS or corneal grafting.
Participants - exclusion criteria1. Age less than 18 years or greater than 40 years
2. Maximal K greater than 60D
3. Minimal Oculus Pentacam pachymetry less than 400 u, to avoid the risk of endothelial damage
4. Evidence of other corneal disease in the eye to be treated (e.g., herpes simplex keratitis)
5. Women who are pregnant or nursing at the time of the initial treatment
6. Presence of significant central corneal opacity
7. Patients unwilling to not wear their rigid contact lenses in the eye to be treated for at least one month before baseline examination, and for the first six months post-operatively (this will be necessary in order to obtain accurate refraction and keratometry readings)
Patient information materialNot available in web format, please use the contact details below to request a patient information sheet
Anticipated start date05/09/2007
Anticipated end date05/09/2008
Status of trialOngoing
Target number of participants20
InterventionsCorneal collagen cross-linking with riboflavin and UV light, plus or minus orthokeratology.

Pre-operatively:
10 patients will be fitted with a specially-made contact lens, which they will need to wear for one week prior to the surgical procedure, in an attempt to change the irregular profile of the cornea prior to undergoing the corneal collagen cross-linking (C3R) treatment. The other 10 patients will not be fitted with any kind of lens.

Surgical procedure:
The surgery will be performed on all 20 patients. Local anaesthesia with anaesthetic eye drops will be utilised. The procedure involves removal of the superficial cell layer of the cornea (epithelium) and then instilling riboflavin eye drops into the eye every three minutes for 30 minutes, until the surgeon judges that an adequate level has been obtained. At that point the ultraviolet light will be directed onto the cornea for 30 minutes to produce collagen cross-linking. Cross-links are small bridges between the fibres in the cornea which strengthen the cornea. Total time for the procedure will be about 1 hour 15 minutes to 1 hour 30 minutes.
Primary outcome measure(s)The difference in the pre- and post-operative:
1. Unaided visual acuity
2. Best corrected visual acuity
3. Refraction
Secondary outcome measure(s)Corneal topographical profile, measured pre-operatively and at one and six months post-operatively.
Sources of fundingMoorfield Eye Hospital Special Trustees (UK)
Sponsor nameMoorfields Eye Hospital NHS Foundation Trust (UK)
Sponsor detailsc/o Professor Roger Hitchings
162 City Road
London
United Kingdom
EC1V 2PD
Sponsor websitehttp://www.moorfields.nhs.uk/Home
Contact nameMr Chad Rostron
Contact detailsDuke Elder Eye Unit (Moorfields Eye Department)
St George's Hospital
Blackshaw Road
London
United Kingdom
SW17 0QT
Contact telephone+44 (0)20 8725 2325
Contact fax+44 (0)20 8725 3026
Contact emailrostron@sgul.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN29378493
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central